Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
Original title: “Takeda leads wave of orexin drugs with potential to upend narcolepsy market”
Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for the condition, Jefferies told investors.
Original title: “Takeda’s narcolepsy nod opens orexin doors”
therapeutic potential of targeting the orexin hypocretin system in sleep disorders
Original title: “Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.”
Designation supports development of novel orexin therapy
Original title: “Lundbeck secures FDA Fast Track for narcolepsy drug”
One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug.
Original title: “Alkermes’ Richard Pops to step down after three-decade run as CEO”